From Dow Jones & Company:

Irvine-based biopharmaceutical company CG Oncology is seeking an initial public offering with the SEC. The company is developing a potential therapeutic for bladder cancer patients unresponsive to Bacillus Calmette-Guerin treatment. Details about shares and estimated price range have not been disclosed. The proceeds will primarily go towards supporting operations. CG Oncology has applied to list its shares on the Nasdaq Global Market under the ticker CGON. The underwriters for the offering are Morgan Stanley, Goldman Sachs & Co., Cantor, and Lifesci Capital.



Read more: Cancer-treatment developer CG Oncology files for IPO